Mori, Yuriko http://orcid.org/0000-0001-5666-0559
Kramer, Vasko
Novruzov, Emil
Mamlins, Eduards
Röhrich, Manuel
Fernández, René
Amaral, Horacio
Soza-Ried, Cristian
Monje, Barbara
Sabbagh, Eduardo
Florenzano, Matías
Giesel, Frederik L.
Undurraga, Álvaro
Funding for this research was provided by:
Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts
Article History
Received: 31 August 2023
Accepted: 4 December 2023
First Online: 20 December 2023
Declarations
:
: All procedures performed in studies involving human participants were approved by the regional ethics committee board (study Nr.: CEC SSM Oriente/05012021) and carried out in accordance with the ethical standards of the institutional and/or national research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.
: FLG has a patent application for quinolone-based FAP-targeting agents for imaging and therapy in nuclear medicine and shares a consultancy group for iTheranostics. FLG is also an advisor at ABX, Telix, Alpha Fusion, and SOFIE Biosciences. The other authors declare no conflict of interest regarding this manuscript.